Revvity expands access to base editing technology with aim to accelerate discovery to cure
Launch of Pin-pointTM base editing reagents improves access to new-generation editing technology
Revvity unveils next-generation preclinical imaging technologies to help scientists drive breakthrough discoveries
WALTHAM, Mass., Revvity, Inc. debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.
Revvity establishes Scientific Centre of Excellence for Genomic Insight in Cambridge
Global health science solutions company Revvity, Inc., has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK. Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of Excellence supports the Company’s fundamental commitment to expanding boundaries in pursuit of a better future for human health.
PerkinElmer’s Horizon Discovery CHOSOURCE platform expands
Existing CHO platform, featuring low cost and no royalty or licence tie-ins, expands with new cell line to help develop biotherapeutics with increased potency and longevity and decreased side effects.
Horizon Discovery extends gene modulation portfolio
CRISPRi innovations provide expanded experimental options and flexibility for researchers, facilitating disease and drug research.
Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced that it has granted two commercial licences for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals Co., Ltd.
Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, has announced the addition of single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio.
Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics
TrueBinding signs multi-product commercial-use licence to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform.
Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively.
Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins
Horizon Discovery's CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield.
Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
Horizon Discovery CHOSOURCE™ platform supports development of immunotherapy for autoimmune diseases
Batavia Biosciences and Immutep use Horizon’s GS knockout CHO K1 cell line expression system to generate high yielding cell line for LAG-3 immunotherapy.
Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
Horizon Discovery expands cell-based CRISPR screening services
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.
Horizon Discovery and Pharmahungary report positive early-stage results for novel micro-RNA therapeutic for ischemic heart diseases
Micro-RNA compound is found suitable for further development following favourable pharmacokinetic and pharmacodynamic study results.
Horizon Discovery grants a multi-product use licence of its GS knockout CHO K1 cell line to NGM Bio
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. (NGM).
Horizon Discovery signs collaboration and licence agreement with Mammoth Biosciences
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announced that it has signed a collaboration and licence agreement with Mammoth Biosciences to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic…
Horizon Discovery introduces predesigned synthetic sgRNAs to streamline CRISPR gene editing workflows
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, has announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful…
Horizon Discovery partners with the Human Protein Atlas
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced that it has entered into a partnership with The Human Protein Atlas (HPA).
Horizon Discovery divests animal models business to Envigo
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announces an agreement to divest the Group’s animal research models business unit to Envigo RMS LLC.
Horizon Discovery reaches integration milestone and launches new website
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today went live with a new website and ecommerce system, marking a significant milestone in the Company’s strategy to fully integrate all tools, technologies and services, including Dharmacon reagents, under the Horizon brand.
Horizon Discovery signs licence agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line.
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic
Batavia Biosciences announced that the company has signed a licence agreement to utilise Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC)…
Horizon Discovery collaborates with St George’s University Hospital and EMQN
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).
Horizon Discovery and Rutgers University to develop next generation gene editing technology
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing technology, known as base editing.